ModAstera Unveils MAEA: A Revolutionary AI Platform for Healthcare Innovation

ModAstera Launches MAEA - A Game-Changer for Healthcare AI Development

In a significant advancement for healthcare technology, ModAstera Inc., based in Tokyo and led by CEO Joshua Owoyemi, has officially unveiled its medical AI development platform, MAEA (Medical AI Engineering Agent). Tailored for small teams and individual researchers, MAEA is now publicly available. During its beta phase, clients reported an impressive average reduction of 80% in data annotation time. Furthermore, one client successfully transitioned from the idea stage to deploying a personalized health application in less than 30 days.

Background and Objective

The practical application of medical AI has traditionally involved several high-cost and resource-intensive steps, including data preparation, the construction of learning pipelines, deployment, and adherence to regulations. MAEA aims to streamline these processes by integrating them into a single platform, significantly reducing the manual workload. This allows researchers and small teams to rapidly validate and deploy medical AI products, promoting greater innovation in the field.

Key Features of MAEA

1. Semi-Automatic Annotation (Image and Video Support)

With just a click, users can select areas of interest within images, prompting the AI to automatically generate annotations. An active learning mechanism continuously enhances labeling efficiency, saving both time and resources.

2. Natural Language AI Model Generation

Users can simply select and upload datasets while inputting their goals in natural language. MAEA will then automatically generate the optimal AI model and training pipeline tailored to the data provided, managing the entire learning, optimization, and evaluation process cohesively.

3. One-Click Deployment (API Provision)

The platform allows users to publish trained models as APIs instantly, facilitating seamless integration into existing applications or the rapid launch of new services.

4. SaMD Documentation Assistance

MAEA supports the creation of necessary documentation for software as a medical device (SaMD) applications, significantly reducing the time-consuming process that typically takes months.

Results from Beta Implementation

Beta clients have witnessed remarkable results: average data annotation time reduced by 80%, with one team completing the process from conceptualization to deployment of a personalized health application in under 30 days.

Launch Date and Access Details

From today, October 21, 2025, MAEA is accessible to small teams and individual researchers. For more information and to create an account, visit ModAstera's official website.

CEO Commentary

"We aim to lower the 'implementation barrier' that exists between medical practice and research. This aspiration drove the development of MAEA. Our goal is to enable researchers to swiftly test their ideas and link them to clinical applications without requiring specialized engineers or substantial resources. We hope this public release accelerates innovation in medical AI for researchers and developers alike," said Joshua Owoyemi, CEO of ModAstera Inc.

About ModAstera Inc.

The inception of ModAstera began with a fortuitous meeting between two visionaries at the global accelerator 'Antler.' Our focus is on fully automating the entire process of developing medical AI through our unique AI agent, MAEA. This innovation has been acknowledged through awards such as winning 'Takeoff Tokyo 2025,' selection as Japan’s representative for the 'Qualcomm AI Program,' and acceptance into the 'J-StarX' overseas dispatch program by the Ministry of Economy, Trade and Industry and JETRO. Our mission is to liberate doctors and researchers through AI, paving the way for a future where everyone has access to the best healthcare.